Antidementiva

  • Isabella Heuser
  • Hans Förstl
Chapter

Zusammenfassung

Derzeit stehen mit den Cholinesterasehemmern (Cholinesterase- Inhibitoren, ChE-I) und Memantin symptomatisch wirksame Antidementiva für die Behandlung der manifesten Alzheimer- Demenz (AD) zur Verfügung. Da die Mehrzahl der Demenzerkrankungen auf der Basis mehrerer unterschiedlicher Arten von Hirnveränderungen – v. a. der Alzheimer-Neurodegeneration – entsteht und mit ähnlichen neurobiologischen Problemen assoziiert ist, kann ein Behandlungsversuch bei Patienten mit anderen Demenzvarianten sinnvoll sein. Die Leistungsfähigkeit und das Befinden von dementen Patienten mit Störungen des Erlebens und Verhaltens kann möglicherweise auch durch Antidepressiva, Antipsychotika und andere Substanzen verbessert werden (sie werden an anderer Stelle abgehandelt, ► Kap. 53 und ► Kap. 55).

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ago Y, Koda K, Takuma K et al (2011) Pharmacological aspects of the acetylcholinesterase inhibitor galantamine. J Pharmacol Sci 116: 6–17CrossRefPubMedGoogle Scholar
  2. Alley GM, Bailey JA, DeMao C et al (2010) Memantine lowers amyloid-s peptide levels in neuronal cultures and in APP/PS1 transgenic mice. J Neurosci Res 88: 143–154CrossRefPubMedCentralPubMedGoogle Scholar
  3. Anand R, Hartman R, Sohn H et al (2003) Impact of study design and patient population on outcomes from cholinesterase inhibitor trials. Am J Geriatr Psychiatry 11: 160–168CrossRefPubMedGoogle Scholar
  4. Arzneimittelkommission der Deutschen Ärzteschaft (2001) Empfehlungen zur Therapie der Demenz. Arzneiverordnungen in der Praxis; Sonderheft Therapieempfehlungen, 2. Aufl. Januar 4: 1–12Google Scholar
  5. Bachinskaya N, Hoerr R, Ihl R (2011) Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761. Findings from a randomized controlled trial. Neuropsychiatr Dis Treat 7: 209–215PubMedCentralPubMedGoogle Scholar
  6. Bachurin S, Bukatina E, Lermontova N et al (2001) Antihistamine agent dimebone as a novel neuroprotector and a cognition enhancer. Ann NY Acad Sci 939: 425–435CrossRefPubMedGoogle Scholar
  7. Bailey JA, Ray B, Greig NH et al (2011) Rivastigmine lowers Aβ and increases sAPPalpha levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS ONE 6(7): e21954CrossRefPubMedCentralPubMedGoogle Scholar
  8. Bal Dit Sollier C, Caplain H, Drouet L (2003) No alteration in platelet function or coagulation induced by EGb 761 in a controlled study. Clin Lab Haematol 25: 251–253CrossRefGoogle Scholar
  9. Bastianetto S, Quirion R (2002) EGb 761 is a neuroprotective agent against beta-amyloid toxicity. Cell Mol Biol (Noisy-le-grand) 48(6): 693–697Google Scholar
  10. Bentue-Ferrer D, Tribut O, Polard E, Allain H (2003) Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs 17: 947–963CrossRefPubMedGoogle Scholar
  11. Bickel U, Thomsen T, Fischer JP et al (1991) Galanthamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice. Neuropharmacology 30: 447–454CrossRefPubMedGoogle Scholar
  12. Birks J (2006) Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 1: CD005593PubMedGoogle Scholar
  13. Birks J, Grimley Evans J, Iakovidou V et al (2009) Rivastigmine for Alzheimer’s disease. Cochrane Review (2): CD001191PubMedGoogle Scholar
  14. Campbell N, Ayub A, Boustani MA et al (2008) Impact of cholinesterase inhibitors on behavioural and psychological symptoms of Alzheimer’s disease: a meta-analysis. 3: 719–728Google Scholar
  15. Campbell N, Boustani M, Limbil T et al (2009a) The cognitive impact of anticholinergics: a clinical review. Clin Intervent Aging 4: 225–233Google Scholar
  16. Campbell N, Boustani MA, Ayub A et al (2009b) Pharmacological management of delirium in hospitalized adults – a systematic evidence review. J Gen Int Med 24: 848–853CrossRefGoogle Scholar
  17. Chow TW, Graff-Guerrero A, Verhoeff NPLG et al (2011) Open-label study of the short-term effects of memantine on FG-PET in frontotemporal dementia. Neuropsychiat Dis Treat 7: 415–424CrossRefGoogle Scholar
  18. Costa MM, Reus VI, Wolkowitz OM et al (1999) Estrogen replacement therapy and cognitive decline in memory-impaired post-menopausal women. Biol Psychiatry 46: 182–188CrossRefPubMedGoogle Scholar
  19. Courtney C, Farrell D, Gray R et al; AD2000 Collaborative Group (2004) Longterm donepezil treatment in 565 patients with Alzheimer´s disease (AD2000): randomised double-blind trail. Lancet 363: 2105–2115Google Scholar
  20. Diehl-Schmid J, Förstl H, Perneczky R et al (2008) A 6-months open label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatry 23: 754–759CrossRefPubMedGoogle Scholar
  21. Doody RS, Gavrilova SI, Sano M et al (2008) Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild to moderate Alzheimer’s disease. Lancet 372: 207–215CrossRefPubMedGoogle Scholar
  22. Eckert A, Keil U, Scherping I et al (2005) Stabilization of mitochondrial membrane potential and improvement of neuronal energy metabolism by Ginkgo biloba extract Egb 761. Ann NY Acad Sci 1056: 474–485CrossRefPubMedGoogle Scholar
  23. Emre M, Aarsland D, Albanese A et al (2004) Rivastigmine for dementia associated with Parkinson´s disease. N Engl J Med 351: 2509–2518CrossRefPubMedGoogle Scholar
  24. Emre M, Tsolaki M, Bonuccelli U et al (2010) Memantine for patients with Parkinson’s disease dementia or dementia with Lewy-bodies: a randomised double-blind placebo-controlled trial. Lancet Neurol 9(10): 969–977CrossRefPubMedGoogle Scholar
  25. Enz A, Boddeke H, Gray J, Spiegel R (1991) Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor. Ann NY Acad Sci 640: 272–275PubMedGoogle Scholar
  26. Epstein NU, Saykin AJ, Risacher S et al (2010) Differences in medication use in the Alzheimer’s disease Neuroimaging initiative. Drugs Aging 27: 677–686CrossRefPubMedCentralPubMedGoogle Scholar
  27. Farlow MR (2006) Use of antidementia agents in vascular dementia: beyond Alzheimer disease. Mayo Clin Proc 81: 1350–1358CrossRefPubMedGoogle Scholar
  28. Farlow M, Veloso F, Moline M et al (2011) Safety and tolerability of donepezil 23 mgin moderate to severe Alzheimer’s disease. BMC Neurology 11: 57CrossRefPubMedCentralPubMedGoogle Scholar
  29. Feldman H, Gauthier S, Hecker J et al; Donepezil MSAD Study Investigators Group (2001) A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 57: 613–620CrossRefPubMedGoogle Scholar
  30. Furey ML, Pietrini P, Haxby JV et al (2008) Selective effects of cholinergic modulation on task performance during selective attention. Neuropsychopharmacology 33: 913–923CrossRefPubMedCentralPubMedGoogle Scholar
  31. Gabelli C (2003) Rivastigmine: an update on therapeutic efficacy in Alzheimer ´s disease and other conditions. Curr Med Res Opin 19: 69–82CrossRefPubMedGoogle Scholar
  32. Gamberini M, Bolliger D, Lurati Buse GA et al (2009) Rivastigmine for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgery – a randomized controlled trial. Crit Care Med 37: 1762–178CrossRefPubMedGoogle Scholar
  33. Geerts H, Grossberg GT (2006) Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer’s disease. J Clin Pharmacol 46: 8S-16SCrossRefPubMedGoogle Scholar
  34. Gill SS, Anderson GM, Fischer HD et al (2009) Syncope and its consequences in patients with dementia receiving cholinesterase-inhibitors. Arch Intern Med 169: 867–873CrossRefPubMedGoogle Scholar
  35. Glodzik L, King KG, Gonen O et al (2008) Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study. Progr Neuro- Psychopharmacol Biol Psychiatry 32: 1005–1012CrossRefGoogle Scholar
  36. Grossberg GT, Edwards KR, Zhao Q (2006) Rationale for combination with galantamine and memantine in Alzheimer’s disease. J Clin Pharmacol 46: 17S-26SCrossRefPubMedGoogle Scholar
  37. Hansen RA, Gartlehner G, Webb AP et al (2008) Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease. Clin Intervent Aging 3: 211–225Google Scholar
  38. Holmes C, Boche D, Wilkinson D et al (2008) Long-term effects of Aβ42 immunisation in Alzheimer’s disease: follow-up of a randomised placebocontrolled phase I trial. Lancet 372: 216–223CrossRefPubMedGoogle Scholar
  39. Hoyer S, Lannert H, Noldner M, Chatterjee SS (1999) Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761). J Neural Transm 106(11–12): 1171–1188CrossRefPubMedGoogle Scholar
  40. Ihl R Bachinskaya N, Korczyn ASD et al (2010) Efficacy and safety of a oncedaily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features. Int J Geriatr Psychiatry, epub ahead of printGoogle Scholar
  41. Jann MW, Shirley KL, Small GW (2002) Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 41(10): 719–739CrossRefPubMedGoogle Scholar
  42. Kieburtz K, McDermott MP, Voss TS et al (2010) A randomized placebo-controlled trial of latrepirdine in Huntington disease. Arch Neurol 67: 154–160CrossRefPubMedCentralPubMedGoogle Scholar
  43. Kim DH, Brown RT, Ding EL et al (2011) Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. JAGS 59: 1019–1031CrossRefGoogle Scholar
  44. Klafki HW, Staufenbiel M, Kornhuber J et al (2006) therapeutic approaches to Alzheimer’s disease. Bain 129: 2840–2855Google Scholar
  45. Kornhuber J (Hrsg), Knöpfel S (2001) Blickpunkt Memantine, 4. Aufl. Aesopus- Verlag, Linkenheim-HochstettenGoogle Scholar
  46. Kurz A, Perneczky R (2010) Novel insights for the treatment of Alzheimer’s disease. Progr Neuropsychopharmacol Biol Psychiatry 35(2): 373–379CrossRefGoogle Scholar
  47. Leuner K, Kurz C, Guidetti G et al (2010) Improved mitochondrial function in brain aging and Alzheimer disease – the new mechanism of action of the old metabolic enhancer piracetam. Front Neurosci, epub ahead of printGoogle Scholar
  48. Liptzin B, Laki A, Garb JL et al (2005) Donepezil in the prevention and treatment of post-surgical delirium Am J Geriat Psychiat 13: 1100–1106CrossRefGoogle Scholar
  49. Lockhart IA, Mitchell SA, Kelly S (2009) Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer’s disease: systematic review of the »real world« evidence. Dement Geriatr Cogn Disord 28: 389–403CrossRefPubMedGoogle Scholar
  50. Lopez-Arrieta JM, Birks J (2001) Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Syst Rev 3: CD000147Google Scholar
  51. Mangialasche F, Solomon A, Winblad B et al (2010) Alzheimer’s disease: clinical trials and drug development. Lancet Neurol 9: 702–716CrossRefPubMedGoogle Scholar
  52. Martinez-Coria H, Green KN, Billings LM et al (2010) Memantine improves cognition and reduces Alzheimer’s-like neuropathology in transgenic mice. Am J Pathol 176: 870–880CrossRefPubMedCentralPubMedGoogle Scholar
  53. McKeith I, Mintzer J, Aarsland D et al and on behalf of the International Psychogeriatric Association Expert Meeting on DLB (2004) Dementia with Lewy bodies. Lancet Neurol 3: 19–28CrossRefPubMedGoogle Scholar
  54. McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer´s disease: recommendations from the National Institute on Aging-Alzheimer´s Association workgroups on diagnostic guidelines for Alzheimer´s disease. Alzheimers Dement 7: 263–269CrossRefPubMedCentralPubMedGoogle Scholar
  55. McShane R, Areosa Sastre A, Minakaran N (2006) Memantine for dementia. Cochrane Database Syst Rev 2: CD003154PubMedGoogle Scholar
  56. Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G (2002) Neuroprotection by memantine against neurodegeneration induced by beta-amyloid (1–40). Brain Res 958: 210–221CrossRefPubMedGoogle Scholar
  57. Modi G, Pillay V, Choonara YE (2010) Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann NY Acad Sci 1184: 154–172CrossRefPubMedGoogle Scholar
  58. Mohs RC, Doody RS, Morris JC et al; »312« Study Group (2001) A 1-year, placebo- controlled preservation of function survival study of donepezil in AD patients. Neurology 57: 481–488CrossRefPubMedGoogle Scholar
  59. Monaghan DT, Jane DE (2009) Pharmacology of NMDA receptors. In: van Dongen AM (ed) Biology of the NMDA receptor. Taylor & Francis, Boca Raton, FLGoogle Scholar
  60. Nakamura Y, Imai Y, Shigeta M et al (2011) A 24-week randomized doubleblind placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer’s disease. Dement Geriatr Cogn Disord Extra 1: 163–179CrossRefGoogle Scholar
  61. Nink K, Schröder H (2001) Arzneimittelverordnungen nach Altersgruppen 2000. Wissenschaftliches Institut der AOK, BonnGoogle Scholar
  62. Ohnishi A, Mihara M, Kamakura H et al (1993) Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy young and elderly subjects. J Clin Pharmacol 33: 1086–1091CrossRefPubMedGoogle Scholar
  63. Overshott R, Karim S, Burns A (2008) Cholinesterase inhibitors for delirium. Cochrane Database Syst Rev (1): CDE005317Google Scholar
  64. Panza F, Frisardi V, Imbimbo BP et al (2010) Gamma-secretase inhibitors for the treatment of Alzheimer’s disease. CNS Neurosci Ther 16: 272–284CrossRefPubMedGoogle Scholar
  65. Patel SS, Attard A, Jacobsen P et al (2010) Acetylcholinesterase inhibitors for the treatment of visual hallucinations in schizophrenia. BMC Psychiatry 10: 69CrossRefPubMedCentralPubMedGoogle Scholar
  66. Peskind ER, Potkin SG, Pomara N et al (2006) Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized controlled trial. Am J Geriatr Psychiatry 8: 704–715CrossRefGoogle Scholar
  67. Pilotto A, Fanceschi M, D’Onofrio G et al (2009) Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology 73: 761–767CrossRefPubMedCentralPubMedGoogle Scholar
  68. Raschetti R, Albanese E, Vanacore N et al (2007) Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Medicine 4: 1818–1828CrossRefGoogle Scholar
  69. Raskind MA, Peskind ER, Wessel T, Yuan W (2000) Galantamine in AD: a 6- month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54: 2261–2268CrossRefPubMedGoogle Scholar
  70. Reisberg B, Doody R, Stoffler A et al; Memantine Study Group (2003) Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 348: 1333–1341CrossRefPubMedGoogle Scholar
  71. Reynolds 3rd CF, Butters MA, Lopez O et al (2011) Maintenance treatment of depression in old age: a randomized double-blind placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry 68: 51–60CrossRefPubMedCentralPubMedGoogle Scholar
  72. Riepe MW, Adler G, Ibach B et al (2006) Adding memantine to rivastigmine therapy in patients with mild-to-moderate Alzheimer’s disease: results of a 12-week, open-label pilot study. Prim Care Companion J Clin Psychiatry 8: 258–263CrossRefPubMedCentralPubMedGoogle Scholar
  73. Roberts JS, Karlawish JH, Uhlmann WR et al (2010) Mild cognitive impairment in clinical care: a survey of American Academy of Neurology members. Neurology 75: 425–431CrossRefPubMedCentralPubMedGoogle Scholar
  74. Rodda J, Morgan S, Walker Z (2009) Are cholinesterase inhibitors effective in the management of behavioural and psychological symptoms of dementia in Alzheimer’s disease? Internat Psychogeriatr 21: 813–824CrossRefGoogle Scholar
  75. Rogers SL, Cooper NM, Sukovaty R et al (1998) Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 46(Suppl 1): 7–12PubMedCentralPubMedGoogle Scholar
  76. Rokem A, Landau AN, Garg D et al (2010) Cholinergic enhancement increases the effects of voluntary attention but does not affect involuntary attention. Neuropsychopharmacology 35: 2538–2544CrossRefPubMedCentralPubMedGoogle Scholar
  77. Rösler M, Anand R, Cicin-Sain A et al (1999) Efficacy and safety of rivastigmine in patients with Alzheimer´s disease: international randomized controlled trial. Br Med J 318: 633–638CrossRefGoogle Scholar
  78. Sampson EL, Raven PR, Ndhlovu PN et al (2007) A randomized double-blind placebo-controlled trial of donepezil hydrochloride for reducing the incidence of postoperative delirium after elective total hip replacement. Int J Geriat Psychiat 22: 343–349CrossRefGoogle Scholar
  79. Sastre J, Lloret A, Borras C et al (2002) Ginkgo biloba extract EGb 761 protects against mitochondrial aging in the brain and in the liver. Cell Mol Biol (Noisy-le-grand) 48: 685–692Google Scholar
  80. Schmidt R, Ropele S, Pendl B et al (2008) Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. J Neurol Neurosurg Psychiat 79: 1312–1317CrossRefPubMedCentralPubMedGoogle Scholar
  81. Schneider LS, De Kosky ST, Farlow MR et al (2005) A randomized, doubleblind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer’s type. Curr Alzheimer Res 2(5): 541–551CrossRefPubMedGoogle Scholar
  82. Singer M, Romero B, Koenig E et al (2005) Alpträume bei Patienten mit Alzheimer Demenz unter Donepezil-Behandlung. Nervenarzt 76: 1127–1128CrossRefPubMedGoogle Scholar
  83. Sinha S, Lieberburg I (1999) Cellular mechanisms of beta-amyloid production and secretion. Proc Natl Acad Sci USA 96: 11049–11053CrossRefPubMedCentralPubMedGoogle Scholar
  84. Sperling R, Aisen PS, Beckett LA et al (2011) Toward defining preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association group. Alzheimer Dementia 7: 280–292CrossRefGoogle Scholar
  85. Sultzer DL, Melrose RJ, Harwood et al (2010) Effect of treatment on regional metabolism in Alzheimer’s disease. Am J Geriat Psychiat 18: 606–614CrossRefGoogle Scholar
  86. Tariot PN, Solomon PR, Morris JC et al (2000) A 5-month, randomized, placebo- controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 54: 2269–2278CrossRefPubMedGoogle Scholar
  87. Tariot PN, Farlow MR, Grossberg GT et al (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291: 317–371CrossRefPubMedGoogle Scholar
  88. Thomas S, Grossberg GT (2009) Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias. Clin Intervent Aging 4: 367–377Google Scholar
  89. Thomas C, Hestermann U, Kopitz J et al (2008) Serum anticholinergic activity and cerebral cholinergic dysfunction: an EEG study in frail elderly with and without delirium BMC Neurosci 9: 86Google Scholar
  90. van Eijk, MMJ, Roes KCB, Honing MLLH et al (2010) Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebocontrolled randomised study. Lancet 376(9755): 1829–1837CrossRefPubMedGoogle Scholar
  91. VFA (Verband Forschender Arzneimittelhersteller) (2004) Gutachten »Defizite in der Arzneimittelverordnung in Deutschland« fur, von: Fricke & Pirke GmbH, 12.10.2004Google Scholar
  92. Vos B, Thienel R, Leucht S et al (2008) Therapie kognitiver Defizite durch AChE-Hemmer bei Patienten mit Schizophrenie. Nervenarzt 79: 47–59CrossRefGoogle Scholar
  93. Weiser M, Rotmensch HH, Korczyn AD et al; Rivastigmine-Risperidone Study Group (2002) A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. Int J Geriatr Psychiatry 17: 343–346CrossRefPubMedGoogle Scholar
  94. Wilcock G, Howe I, Coles H et al and Members of the GAL-GBR-2 Study Group (2003) A long-term comparison of galantamine and donepezil in the treatment of Alzheimer´s disease. Drugs Aging 20: 777–789CrossRefPubMedGoogle Scholar
  95. Wilkinson DG, Passmore AP, Bullock R et al (2002) A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer’s disease. Int J Clin Pract 56: 441–446PubMedGoogle Scholar
  96. Winblad B, Engedal K, Soininen H et al; Donepezil Nordic Study Group (2001) A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57: 489–495CrossRefPubMedGoogle Scholar
  97. Winblad B, Cummings J, Andreasen N et al (2007) A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsule. Int J Geriatr Psychiatry 22(5): 456–467CrossRefPubMedGoogle Scholar
  98. Winblad B, Fioravanti M, Dolezal T et al (2008) Therapeutic use of nicergoline. Clin Drug Investig 28: 533–552CrossRefPubMedGoogle Scholar
  99. Woodruff-Pak DS, Vogel RW 3rd, Wenk GL (2001) Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci USA 98: 2089–2094CrossRefPubMedCentralPubMedGoogle Scholar
  100. Wu J, Li Q, Bezprovanny I (2008) Evaluation of dimebon in cellular model of Huntington’s disease. Mol Neurodegeneration 3: 15CrossRefGoogle Scholar
  101. Yancheva S, Ihl R, Nikolova G et al (2009) Ginkgo biloba extract EGb 761, donepezil or both combined in the treatment of Alzheimer’s disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. Aging Ment Health 13: 183–190CrossRefPubMedGoogle Scholar
  102. Yao Z, Drieu K, Papadopoulos V (2001) The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Res 889: 181–190CrossRefPubMedGoogle Scholar
  103. Zhao X, Marszalec W, Toth PT et al (2006) In vitro galantamine-memantine co-application: mechanism of beneficial action. Neuropharmacology 51: 1181–1191CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Isabella Heuser
    • 1
  • Hans Förstl
    • 2
  1. 1.Klinik und Hochschulambulanz für Psychiatrie und PsychotherapieCharité Campus Benjamin FranklinBerlin
  2. 2.Klinik und Poliklinik für Psychiatrie und PsychotherapieKlinikum rechts der Isar der TU MünchenMünchen

Personalised recommendations